Background: The impact of ixekizumab treatment for psoriasis on cardiovascular-related parameters in patients is unknown.
lipoprotein cholesterol, triglyceride, apolipoprotein A1, apolipoprotein B, or fasting glucose levels or for systolic/diastolic blood pressure at 60 weeks. Importantly, low-density lipoproteinetoehigh-density lipoprotein ratios remained stable during the induction and maintenance periods. HsCRP concentrations were significantly reduced versus placebo at 12 weeks and remained reduced at 60 weeks, although not significantly. Although transient changes were observed for some parameters during the induction period, these changes did not persist into the maintenance period.
Limitations: A lack of echocardiogram evaluations.
Conclusions: Ixekizumab had a neutral impact on cardiovascular-related parameters in patients with psoriasis. ( J Am Acad Dermatol 2018;79:104-9.)
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Patients with psoriasis have a high prevalence of cardiovascular risk factors and comorbidities. 1 Some cardiovascular comorbidities are significantly associated with the severity of psoriasis. 2 The immunopathogenesis of psoriasis and atherosclerosis are similar; both are mediated by type 1 and type 17 helper T cells, which may explain the increased cardiovascular disease risk observed in patients with psoriasis. [3] [4] [5] As such, it is plausible to expect that biologic therapies for psoriasis could alter the cardiovascular risk profile in patients with psoriasis and potentially affect major adverse cardiovascular events (MACEs).
Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin 17A (IL-17A) and is effective for the treatment of moderate-tosevere plaque psoriasis. [6] [7] [8] Integrated analyses of ixekizumab safety data from 7 psoriasis clinical trials found no increased risk of MACEs associated with the use of ixekizumab. 9 Nonetheless, the impact of ixekizumab on other cardiovascular-related parameters is unknown. Thus, we investigated several cardiovascular-related parameters in patients with moderate-to-severe plaque psoriasis who were undergoing treatment with ixekizumab.
METHODS

Study design and patient information
Data were obtained from randomized, These studies enrolled adults ($18 years old) with moderate-tosevere plaque psoriasis; the inclusion and exclusion criteria were previously published.
6,7 UNCOVER-1, UN COVER-2, and UNCOVER-3 had 12-week placebocontrolled induction periods, which included an etanercept comparator group in UNCOVER-2 and UNCOVER-3, and patients were treated with placebo, 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 2 weeks, or 50 mg of etanercept biweekly (only UNCOVER-2 and UNCOVER-3). Patients treated with ixekizumab received an initial 160-mg starting dose. At week 12, responders to ixekizumab (static Physician's Global Assessment score, 0,1) in UNCOVER-1 and UNCOVER-2 were randomly reassigned to placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60 for the maintenance period. Data from patients treated with ixekizumab every 12 weeks were not included because this regimen is not approved. Trial protocols were approved by each sites' institutional review board or ethics committee. Informed consent was obtained from participants. The research was carried out in accordance with the Declaration of Helsinki.
Laboratory and vital sign measurements
Blood samples (approximately 15 mL) were collected at each visit through week 60 for fasting lipid profiles (in weeks 0, 4, 12, 24, and 60),
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Statistical analyses
Integrated analyses were performed for the induction period through week 12 from UNCOVER-1, UNCOVER-2, and UNCOVER-3 (the primary psoriasis placebo-controlled integrated analysis set [ Supplemental Fig 1, A; available at http://www. jaad.org]) and UNCOVER-2 and UNCOVER-3 (the psoriasis placebo-and active-controlled integrated analysis set [ Supplemental Fig 1, B ; available at http://www.jaad.org]) and for the maintenance period through week 60 for UNCOVER-1 and UNCOVER-2 (the psoriasis maintenance integrated analysis set [ Supplemental Fig 1, C ; available at http://www.jaad.org]). Analyses of the results at week 12 and week 60 were conducted on the basis of an analysis of covariance with treatment, study, and baseline values included within the model. P values were derived from comparisons made with the placebo or active comparator groups.
RESULTS
Baseline patient demographics and characteristics are listed in Table I and Supplemental Table I (available at http://www.jaad.org) for the primary psoriasis placebo-controlled integrated analysis set and the psoriasis placebo-and active-controlled integrated analysis set, respectively. Baseline demographics were similar between the treatment and placebo arms, representing a typical clinical trial population for moderate-to-severe psoriasis.
Overall, no significant changes were observed in laboratory parameters at 60 weeks of treatment with ixekizumab. Of clinical relevance, the low-density lipoprotein (LDL)-toehigh-density lipoprotein (HDL) ratio was stable, with no observed changes from baseline through 60 weeks (Fig 1) . Similarly, the serum concentrations of total cholesterol, triglycerides, apolipoprotein B, apolipoprotein A1, and fasting glucose measured at week 60 were comparable in patients treated with ixekizumab and those receiving placebo during the maintenance period (Table II) . A few significant but transient changes were observed in some serum parameters measured at week 12 relative to placebo, including decreased high-sensitivity C-reactive protein (hsCRP), increased LDL, and increased total cholesterol concentrations after treatment with ixekizumab every 2 weeks in the induction period, but these changes were not maintained though week 60.
Diastolic and systolic blood pressures were also investigated in the patients (Supplemental Table II ; available at http://www.jaad.org), revealing no changes from baseline throughout the study. No differences in electrophysiologic parameters were observed in the induction or maintenance periods for ixekizumab-treated patients with the exception of the small and most likely clinically unmeaningful difference in PR duration observed between those taking ixekizumab every 2 weeks and those taking the placebo (Supplemental Table III ; available at http://www.jaad.org). Body weight did not change from baseline throughout the study in patients treated with ixekizumab.
In general, all results were similar for the etanercept treatment group, but at week 12 significant differences were observed between the etanercept and ixekizumab treatment groups for apolipoprotein B and A1 concentrations (Supplemental Table IV ; available at http://www.jaad.org), but not for their respective lipoprotein complexes, or for QRS duration (Supplemental Table V ; available at http://www. jaad.org). No other significant differences were observed between the ixekizumab and etanercept treatment groups (Supplemental Tables IV-VI [ . Relative to placebo, significant differences were observed after etanercept treatment for total cholesterol, triglycerides, and hsCRP concentrations, as well as for weight and PR duration, but these parameters failed to demonstrate significant differences between ixekizumab and etanercept treatment.
DISCUSSION
Markers of cardiovascular disease were investigated in patients participating in the induction (12 weeks) and maintenance periods (12-60 weeks) of the phase 3 trials of ixekizumab for the treatment of patients with psoriasis. In this population, ixekizumab, a monoclonal antibody that selectively targets IL-17A, 8 has been demonstrated to be highly efficacious for the treatment of moderate-to-severe plaque psoriasis. 6, 7 Despite its mechanism of action and efficacy in the reduction of skin inflammation, the impact of ixekizumab on cardiovascular-related parameters was neutral. However, ixekizumab treatment reduced hsCRP levels, indicating that systemic inflammation was reduced in patients. Still, the true clinical implications of this change in magnitude are not clear.
Beyond our study, in the PHOENIX psoriasis trials, ustekinumab had a neutral impact on cardiovascular-related parameters. 10 However, it is well established that cholesterol levels can decrease in patients with chronic inflammatory conditions and therapeutic dampening of inflammation can lead to increased levels of total, LDL, and HDL cholesterols. 11 Our observations and those from the PHOENIX trials are in line with findings of Holzer et al, 12 who reported that treatment with certain antipsoriatic therapies did not affect serum cholesterol concentrations but was associated with changes in HDL composition and cholesterol efflux function.
In our study, we demonstrated that the LDL/HDL ratio, which is a predictor for myocardial infarction, 13 is stable after induction dosing (12 weeks) and maintenance dosing (60 weeks) in patients treated with ixekizumab. We did not investigate lipid composition or function; thus, further studies are warranted to investigate the impact of ixekizumab treatment on lipid composition and function in patients with psoriasis.
This study has both strengths and limitations. Overall, the patient population was large and representative of the general population of individuals with moderate-to-severe psoriasis. In addition, all laboratory measurements were obtained from a central laboratory, thereby increasing the reliability and reproducibility of the measurements. Conversely, because these results are derived from J AM ACAD DERMATOL VOLUME 79, NUMBER 1 randomized placebo-controlled trials, participating patients had to meet specific inclusion and exclusion criteria. However, the characteristics of the included patients were comparable to those treated with IL-17A inhibitors in a real-life setting. 14 As these were not cardiovascular-focused trials, robust measures of cardiovascular function, other than electrocardiograms, were not performed. In addition, Framingham risk scores were not calculated, but we note that no associations have previously been identified between ixekizumab and MACEs. 9 Nonetheless, additional studies are warranted as part of future ixekizumab trials and postmarketing surveillance to help improve our understanding of the long-term impact of ixekizumab on lipid function, cardiovascular-related parameters, and cardiovascular risk in patients.
In conclusion, we have demonstrated that the overall impact of ixekizumab on several cardiovascular-related parameters is neutral. Combining these results with those seen in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study 15 suggests that in clinical practice, prescribing ixekizumab should not alter decisions to HDL, High-density lipoprotein; hsCRP, high sensitivity C reactive protein; IQR, interquartile range; IXEQ2W, ixekizumab every 2 weeks; IXEQ4W, Ixekizumab every 4 weeks; LDL, low-density lipoprotein; PBO, placebo; SD, standard deviation; VLDL, very-low-density lipoprotein. *Results derived from primary psoriasis placebo-controlled integrated analysis set. y Results derived from psoriasis maintenance integrated analysis set. z P \ .05 versus PBO. Obese/overweight, n (%) 25 (7) 68 (9) 52 (7) 46 (6) Hyperlipidemia, n (%)
21 (6) 37 (5) 26 (4) 38 (5) Hypertension, n (%)
118 (33) 221 (30) 190 (26) 197 (27) Type 2 diabetes mellitus, n (%) 33 (9) 62 (8) 79 (11) 56 (8) ETN, Etanercept; IXEQ2W, ixekizumab every 2 weeks; IXEQ4W, ixekizumab every 4 weeks; PASI, Psoriasis Area and Severity Index; PBO, placebo; SD, standard deviation.
Supplemental Table II . Body weight and diastolic and systolic blood pressure measurements in patients with moderate-to-severe psoriasis treated with placebo, ixekizumab every 4 weeks, or ixekizumab every 2 weeks in the induction period through week 12 and in the maintenance period through week 60 (9) 80 (9) 80 (9) 80 (10) 79 (9) Mean change from baseline, mm Hg (SD) À0.4 (9) 0.1 (9) À0.4 (9) À0.0 (9) À0.6 (9) Systolic blood pressure Mean baseline, mm Hg (SD) 128 (14) 127 (14) 127 (14) 126 (14) 126 ( 
